On November 1, 2018, NeuroPointDX announced the commercial launch of its NPDX AA test, which tests for the potential of autism spectrum disorder (ASD) in children as young as 18 months of age. The test identifies metabolic subtypes in about 30% of children with autism spectrum disorder (ASD), based on findings from the largest clinical study of the metabolism of children with ASD. Additionally, the metabolic information provided by the test can be used to develop a more precise treatment strategy for a child with ASD. The test detects amine imbalances in the blood plasma of children. These imbalances are . . .